Roche moves obesity drug to pivotal trials after mid-stage success
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Pfizer, FDA, BioMarin, worst CEO of 2025: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Pharma’s ‘Dr. Optimistic’ is worried about the industry’s future
In July 2006, The New York Times sent young reporter Alex Berenson to Pfizer to interview me about…
Mutual mistrust: FDA staff wary as Høeg becomes top drug regulator
WASHINGTON — In 2008, Tracy Beth Høeg, then a resident physician and ultramarathon runner, expressed dismay at vice…
FDA reviewers didn’t get to vote on first priority voucher drug
WASHINGTON — The Food and Drug Administration has promised companies that earn a Commissioner’s National Priority Voucher a one-…
New FDA priority review vouchers go to Lilly, Novo, Vertex
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s…
Big Pharma’s ‘patient advocacy’ needs to remember patients’ needs
Every year, pharmaceutical companies spend millions on “patient advocacy.” At its best, this supports families, advances science, and…
FDA moves to ease path for biosimilars as Trump seeks to cut drug costs – statnews.com
FDA moves to ease path for biosimilars as Trump seeks to cut drug costs statnews.com US FDA proposes moves…
Eli Lilly, Sarepta, Pfizer, Medicare, Novo: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Health Care Inc.: STAT investigates hospital infections reporting
This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here. ~*~*~Don’t talk to…